Report of Foreign Issuer (6-k)
December 08 2015 - 4:16PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934
For the month of December
Commission File Number 001-37518
Benitec
Biopharma Limited
(Translation of registrant’s name into English)
F6A, 1-15 Barr Street
Balmain, NSW 2041
Australia
(Address of principal
executive office)
Indicate by check mark whether the registrant files or will
file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F x Form 40-F ¨
Indicate by check mark if the registrant is submitting the Form
6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ¨
Indicate by check mark if the registrant is submitting the Form
6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ¨
Indicate by check mark whether the registrant by furnishing
the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b)
under the Securities Exchange Act of 1934.
Yes ¨ No x
If “Yes” is marked, indicate below the file number
assigned to the registrant in connection with Rule 12g3-2(b): n/a
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly
authorized.
|
|
Benitec Biopharma Limited |
|
|
|
|
|
|
Date: 12/08/15 |
By: |
/s/ GREG WEST |
|
Name: |
Greg West |
|
Title: |
Company Secretary |
EXHIBIT INDEX
Exhibit
Number |
|
Description |
99.1 |
|
Announcement, dated 12/08/15, to Australian Securities Exchange |
Exhibit 99.1
Greg West, Benitec’s
Chief Financial Officer and Company Secretary, Named Interim Chief Executive Officer
Benitec’s Chief Executive
Officer, Dr. Peter French, Steps Down
Sydney
Australia, December 8, 2015: The Board of Directors of Benitec Biopharma Limited (ASX: BLT; NASDAQ: BNTC; NASDAQ: BNTCW) has
today announced that Dr. Peter French will step down as Chief Executive Officer and Managing Director of the Company. Mr.
Greg West, Benitec’s Chief Financial Officer and Company Secretary, has been appointed as interim Chief Executive Officer.
Benitec’s Board has commenced
a global search for a new CEO and it is intended that the new CEO will be based in the United States. This is in line with the
Company’s goal to establish a stronger profile and management team in the United States, following its NASDAQ listing in
August 2015 and establishment of the Bremner Laboratory in San Francisco, California, in September 2014.
Benitec’s Chairman, Mr.
Peter Francis, said, “Over the past five years, Dr. Peter French’s leadership has been instrumental in Benitec’s
transformation from a company that had limited resources and no clinical programs, to become a clinical stage company, with a valuable
development pipeline and a solid cash position. The Board and Management wish Dr. French all the best for the future and we sincerely
thank him for his outstanding contribution to Benitec’s growth. The Board will work closely with Mr. West until a new CEO
is appointed, and we look forward to updating our shareholders as we move forward with the transition.”
About Benitec Biopharma
Limited:
Benitec Biopharma Limited (ASX:
BLT; NASDAQ: BNTC; NASDAQ: BNTCW) is a clinical-stage biotechnology company developing innovative therapeutics based on its patented
gene-silencing technology called ddRNAi or ‘expressed RNAi’. Based in Sydney, Australia with labs in Hayward, CA (USA) and collaborators
and licensees around the world, the company is developing ddRNAi-based therapeutics for chronic and life-threatening human conditions
including hepatitis C and B, wet age-related macular degeneration and OPMD. Benitec has also licensed ddRNAi to other biopharmaceutical
companies for applications including HIV/AIDS, Huntington’s Disease, chronic neuropathic pain and retinitis pigmentosa. For further
information regarding Benitec and its activities, please contact the persons below, or visit the Benitec website at www.benitec.com
Safe Harbor Statement:
This press release contains
“forward-looking statements” within the meaning of section 27A of the US Securities Act of 1933 and section 21E of the
US Securities Exchange Act of 1934. Benitec has tried to identify such forward-looking statements by use of such words as “expects,”
“intends,” “hopes,” “anticipates,” “believes,” “could,” “may,” “evidences”
and “estimates,” and other similar expressions, but these words are not the exclusive means of identifying such statements.
Such statements include, but are not limited to, any statements relating to Benitec’s pipeline of ddRNAi-based therapeutics, including
the initiation, progress and outcomes of clinical trials and any other statements that are not historical facts. Such forward-looking
statements involve risks and uncertainties, including, but not limited to, risks and uncertainties relating to the difficulties
or delays in our plans to develop and potentially commercialize our product candidates, the timing of the initiation and completion
of preclinical and clinical trials, the timing of patient enrolment and dosing in clinical trials, the timing of expected regulatory
filings, the clinical utility and potential attributes and benefits of ddRNAi and our product candidates, potential future out-licenses
and collaborations, our intellectual property position and duration of our patent portfolio, the ability to procure additional
sources of financing and other risks detailed from time to time in filings that Benitec makes with US Securities and Exchange Commission,
including our most recent annual report on Form 20-F and our reports on Form 6-K. Such statements are based on management’s current
expectations, but actual results may differ materially due to various factors, including those risks and uncertainties mentioned
or referred to in this press release. Accordingly, you should not rely on those forward-looking statements as a prediction of actual
future results.
Contacts:
Company |
Investor relations |
United States |
|
|
|
Carl Stubbings
Chief Business Officer
Tel: +61 (2) 9555 6986
Email: cstubbings@benitec.com |
Annabel Murphy
Head of Investor Relations & Corporate Communications
Tel: +61 (2) 9555 6986
Email: amurphy@benitec.com |
PCG Advisory Group
Adam Holdsworth
Managing Director of Investor Relations
Tel: + 1 646-862-4607
Email: adamh@pcgadvisory.com
Sean Leous
Managing Director of Public Relations
Tel: +1 646-863-8998
Email: sleous@pcgadvisory.com |
Benitec Biopharma (NASDAQ:BNTC)
Historical Stock Chart
From Mar 2024 to Apr 2024
Benitec Biopharma (NASDAQ:BNTC)
Historical Stock Chart
From Apr 2023 to Apr 2024